Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

$638.88 -3.71 (-0.58%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$634.44 -4.44 (-0.69%)

As of 05/22/2026 07:55 PM Eastern

Compare

Regeneron Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 27 Analyst Ratings

Sell
0

Hold
10

Buy
17

Based on 27 Wall Street analysts who have issued ratings for Regeneron Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 10 have given a hold rating, 15 have given a buy rating, and 2 have given a strong buy rating for REGN.

Consensus Price Target

$792.65
24.07% Upside

According to the 27 analysts' twelve-month price targets for Regeneron Pharmaceuticals, the average price target is $792.65. The highest price target for REGN is $995.00, while the lowest price target for REGN is $255.00. The average price target represents a forecasted upside of 24.07% from the current price of $638.88.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for REGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

REGN Analyst Ratings Over Time

Type	Current Forecast 5/23/25 to 5/23/26	1 Month Ago 4/23/25 to 4/23/26	3 Months Ago 2/22/25 to 2/22/26	1 Year Ago 5/23/24 to 5/23/25
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	15 Buy rating(s)	17 Buy rating(s)	14 Buy rating(s)	18 Buy rating(s)
Hold	10 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$792.65	$818.13	$793.81	$884.79
Forecasted Upside	24.07% Upside	6.80% Upside	1.81% Upside	50.39% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

REGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

REGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Regeneron Pharmaceuticals Stock vs. The Competition

Type	Regeneron Pharmaceuticals	Medical Companies	Broader Market
Consensus Rating Score	2.70	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	24.07% Upside	1,714.95% Upside	15.09% Upside
News Sentiment Rating	Neutral News See Recent REGN News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/19/2026	Canaccord Genuity Group 4 of 5 stars	John Newman 3 of 5 stars	Lower Target	Buy	$1,057.00 ➝ $875.00	+39.73%
5/18/2026	BMO Capital Markets 4 of 5 stars	Evan David 3 of 5 stars	Lower Target	Outperform	$900.00 ➝ $730.00	+16.09%
5/18/2026	Truist Financial 3 of 5 stars	Gregory Renza Not Rated	Lower Target	Buy	$796.00 ➝ $778.00	+24.55%
5/18/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$950.00 ➝ $850.00	+35.88%
5/18/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Sector Perform	$762.00 ➝ $707.00	+13.43%
5/18/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$800.00 ➝ $700.00	+12.30%
5/18/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Biren Amin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$875.00 ➝ $855.00	+37.17%
5/18/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$900.00 ➝ $700.00	+0.25%
5/18/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Berens Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$792.00 ➝ $641.00	-8.20%
5/1/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yatin Suneja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$975.00 ➝ $995.00	+41.25%
Read now. Do not delete. You’ve been warned. (Ad) Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change. Don’t be left behind. Click here now.
4/30/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$923.00 ➝ $917.00	+29.94%
4/23/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tyler Van Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$880.00 ➝ $960.00	+26.14%
4/23/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$800.00	+5.03%
4/10/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$769.00 ➝ $796.00	+6.60%
4/8/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Pickering Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$925.00 ➝ $921.00	+20.76%
3/27/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold (C)
2/6/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
2/2/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Biegler Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$750.00 ➝ $865.00	+14.68%
1/22/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Cory Kasimov Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$750.00 ➝ $875.00	+15.64%
1/7/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tim Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Buy	$627.00 ➝ $860.00	+10.75%
11/24/2025	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
11/24/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Louise Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Perform	$650.00 ➝ $770.00	-0.01%
11/7/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Trung Huynh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$595.00 ➝ $660.00	+2.02%
9/2/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Moderate Buy
8/27/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$813.00 ➝ $831.00	+41.41%
8/14/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
6/30/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jasper Hellweg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold
4/30/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$917.00 ➝ $804.00	+36.25%
4/25/2025	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Skorney Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$759.00 ➝ $652.00	+8.71%
2/4/2025	Bernstein Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$1,070.00 ➝ $1,000.00	+44.18%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform	$1,150.00	+46.96%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:45 PM ET.

Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 22, 2026. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com.

Regeneron Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

The current stock price is around $720, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
Regeneron Pharmaceuticals, Inc. has a strong pipeline of biologic therapies, indicating potential for future revenue growth as new products are developed and commercialized.
The company recently announced a strategic collaboration with Parabilis Medicines, which could lead to significant milestone payments and royalties, enhancing its financial outlook.
With institutional investors holding over 83% of the company's stock, there is a strong level of confidence from large financial entities, which can be a positive indicator for retail investors.
The company has a low dividend payout ratio of 9.16%, suggesting that it retains a significant portion of its earnings for reinvestment, which could drive future growth.

Regeneron Pharmaceuticals
Bear Case

Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

Recent setbacks in clinical trials, such as the phase 3 melanoma trial for fianlimab missing its main goal, have weakened confidence in some of the company's high-profile pipeline assets.
Analyst downgrades have occurred following the trial results, with several brokerages lowering their price targets, indicating a more cautious outlook on the stock's performance.
Despite a strong institutional presence, insider selling activity has been noted, which may raise concerns about the confidence of company executives in the stock's future performance.
The current dividend yield is relatively low at 0.6%, which may not attract income-focused investors looking for higher returns from dividends.
Market sentiment has been mixed, with some analysts issuing hold ratings, suggesting that the stock may not be a strong buy at this time.

REGN Forecast - Frequently Asked Questions

According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Regeneron Pharmaceuticals is $792.65, with a high forecast of $995.00 and a low forecast of $255.00.

27 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 10 hold ratings, 15 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares.

According to analysts, Regeneron Pharmaceuticals's stock has a predicted upside of 24.07% based on their 12-month stock forecasts.

Over the previous 90 days, Regeneron Pharmaceuticals's stock had 1 downgrade by analysts.

Regeneron Pharmaceuticals has been rated by research analysts at Barclays, BMO Capital Markets, Canaccord Genuity Group, Cantor Fitzgerald, Citigroup, Guggenheim, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Piper Sandler, Royal Bank Of Canada, Sanford C. Bernstein, TD Cowen, Truist Financial, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Regeneron Pharmaceuticals more than other "medical" companies. The consensus rating for Regeneron Pharmaceuticals is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how REGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Regeneron Pharmaceuticals Recommendations

This page (NASDAQ:REGN) was last updated on 5/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target